Bieber Becomes Biopharmaceuticals Development Head At Sandoz
Florian Bieber is to become head of development for Sandoz’ biopharmaceuticals division, after Mark Levick agreed to take up the post of CEO at Alvotech.
You may also be interested in...
Mark Levick, Sandoz’ head of development for biopharmaceuticals, has been chosen to become CEO of Alvotech from August.
Slower sales growth by its Biopharmaceuticals unit amid competitive pressures in the US, combined with weakness in its Retail Generics and Anti-Infectives franchises, led Sandoz to report an overall 8% sales slide in the first quarter of this year.
GlaxoSmithKline’s established products head, Richard Saynor, will return to Sandoz later this year to lead the Novartis division.